Compare AKA & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKA | RANI |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 106.9M |
| IPO Year | 2021 | 2021 |
| Metric | AKA | RANI |
|---|---|---|
| Price | $10.67 | $0.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.33 | $7.50 |
| AVG Volume (30 Days) | 2.7K | ★ 916.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $1,633,000.00 |
| Revenue This Year | $6.14 | $274.77 |
| Revenue Next Year | $4.89 | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.44 | ★ 58.85 |
| 52 Week Low | $8.42 | $0.44 |
| 52 Week High | $16.38 | $3.87 |
| Indicator | AKA | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 52.57 |
| Support Level | $10.38 | $0.72 |
| Resistance Level | $11.70 | $0.83 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 28.55 | 38.27 |
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.